Dewpoint Therapeutics Dewpoint is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Novo Nordisk, Evotec and Chemify. Dewpoint scientists work to translate condensate biology into breakthrough treatments for diseases previously considered untreatable.  Please be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Dewpoint Therapeutics. Dewpoint never conducts its interviewing or recruiting processes via messaging apps, freelance sites, or social media platforms (i.e., Facebook, WhatsApp, Telegram, Signal, etc.) except for LinkedIn Recruiter. All communication originating from the Dewpoint team, including those communications relating to any job opportunities, comes through an official Dewpoint email address ending in “@dewp